Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories and Clinical Trials Site at Hadassah Medical Center in Jerusalem, Israel

Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories and Clinical Trials Site at Hadassah Medical Center in Jerusalem, Israel

<0> BrainStorm Cell Therapeutics Inc.Adrian Harel, Ph.D., CEO+972-3-9236384 </0>

BrainStorm Cell Therapeutics (OTC: BCLI), a leading developer of adult stem cell technologies and CNS therapeutics, announced that Rasheda Ali Walsh, daughter of the legendary Muhammad Ali, visited the Company’s laboratories as well as its cleanrooms at Hadassah Medical Center, where she received a briefing on the company’s clinical trial conducted there. Ms. Ali Walsh, an internationally known advocate for promoting research and awareness of neurodegenerative diseases, is a member of the Advisory Board of BrainStorm.

BrainStorm’s President, Mr. Chaim Lebovits, and CEO Dr. Adrian Harel accompanied Ms. Ali Walsh for a meeting with Prof. Dimitrios Karussis, Principal Investigator of the Company’s ongoing Phase I/II clinical trial at Hadassah, and Prof. Tamir Ben-Hur, Head of the Neurology Department. The group discussed the latest innovative treatments for neurodegenerative diseases and BrainStorm’s leading role in this area.

“Having heard so much about the recent positive interim safety report and the outstanding progress being made by BrainStorm at Hadassah, I felt the need to actually meet the team in person,” commented Ms. Ali. “The amazing work being done here gives a ray of hope to patients and families worldwide that autologous stem cell transplants may be the answer they’ve been waiting for to overcome neurodegenerative diseases.”

According to Dr. Adrian Harel, BrainStorm’s CEO, “The support and encouragement by world-renowned individuals like Rasheda Ali is important for increasing awareness of the need for a cure for debilitating neurodegenerative diseases. We are hopeful that this awareness will lead to more widespread efforts by governments and health organizations worldwide to fund research in this area and provide assistance to patients and their families.”

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at .

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.